1. Home
  2. AMC vs IMNM Comparison

AMC vs IMNM Comparison

Compare AMC & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMC Entertainment Holdings Inc.

AMC

AMC Entertainment Holdings Inc.

HOLD

Current Price

$2.60

Market Cap

2.4B

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$26.94

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMC
IMNM
Founded
1920
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.5B
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
AMC
IMNM
Price
$2.60
$26.94
Analyst Decision
Hold
Strong Buy
Analyst Count
4
10
Target Price
$2.03
$32.80
AVG Volume (30 Days)
18.1M
1.1M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.40
EPS
N/A
N/A
Revenue
$4,848,900,000.00
$6,941,000.00
Revenue This Year
$11.41
N/A
Revenue Next Year
$5.18
$1,127.34
P/E Ratio
N/A
N/A
Revenue Growth
4.57
N/A
52 Week Low
$0.93
$8.67
52 Week High
$3.18
$30.06

Technical Indicators

Market Signals
Indicator
AMC
IMNM
Relative Strength Index (RSI) 54.02 55.24
Support Level $2.32 $19.28
Resistance Level $3.00 $30.06
Average True Range (ATR) 0.14 1.13
MACD -0.01 -0.28
Stochastic Oscillator 61.41 44.07

Price Performance

Historical Comparison
AMC
IMNM

About AMC AMC Entertainment Holdings Inc.

AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. The company owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: